These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 34439532)
1. Targeted Ablation of Primary Cilia in Differentiated Dopaminergic Neurons Reduces Striatal Dopamine and Responsiveness to Metabolic Stress. Mustafa R; Rawas C; Mannal N; Kreiner G; Spittau B; Kamińska K; Yilmaz R; Pötschke C; Kirsch J; Liss B; Tucker KL; Parlato R Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439532 [TBL] [Abstract][Full Text] [Related]
2. Multi-Electrode Array Analysis Identifies Complex Dopamine Responses and Glucose Sensing Properties of Substantia Nigra Neurons in Mouse Brain Slices. Mannal N; Kleiner K; Fauler M; Dougalis A; Poetschke C; Liss B Front Synaptic Neurosci; 2021; 13():635050. PubMed ID: 33716704 [TBL] [Abstract][Full Text] [Related]
3. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. Duda J; Pötschke C; Liss B J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375 [TBL] [Abstract][Full Text] [Related]
4. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease. Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060 [TBL] [Abstract][Full Text] [Related]
5. Effect of ghrelin on the motor deficit caused by the ablation of nigrostriatal dopaminergic cells or the inhibition of striatal dopamine receptors. Suda Y; Kuzumaki N; Narita M; Hamada Y; Shibasaki M; Tanaka K; Tamura H; Kawamura T; Kondo T; Yamanaka A; Narita M Biochem Biophys Res Commun; 2018 Feb; 496(4):1102-1108. PubMed ID: 29378186 [TBL] [Abstract][Full Text] [Related]
6. Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation. Proença MB; Dombrowski PA; Da Cunha C; Fischer L; Ferraz AC; Lima MM Neuropharmacology; 2014 Jan; 76 Pt A():118-26. PubMed ID: 24012539 [TBL] [Abstract][Full Text] [Related]
7. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509 [TBL] [Abstract][Full Text] [Related]
8. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model. Qi X; Davis B; Chiang YH; Filichia E; Barnett A; Greig NH; Hoffer B; Luo Y J Neurochem; 2016 Sep; 138(5):746-57. PubMed ID: 27317935 [TBL] [Abstract][Full Text] [Related]
9. Dopamine neuronal protection in the mouse Substantia nigra by GHSR is independent of electric activity. Stutz B; Nasrallah C; Nigro M; Curry D; Liu ZW; Gao XB; Elsworth JD; Mintz L; Horvath TL Mol Metab; 2019 Jun; 24():120-138. PubMed ID: 30833218 [TBL] [Abstract][Full Text] [Related]
10. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice. Shan X; Chi L; Bishop M; Luo C; Lien L; Zhang Z; Liu R Stem Cells; 2006 May; 24(5):1280-7. PubMed ID: 16424396 [TBL] [Abstract][Full Text] [Related]
11. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH Life Sci; 1987 Jan; 40(2):193-202. PubMed ID: 3491946 [TBL] [Abstract][Full Text] [Related]
12. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease. Collier TJ; Sortwell CE; Elsworth JD; Taylor JR; Roth RH; Sladek JR; Redmond DE J Comp Neurol; 2002 Jan; 442(4):320-30. PubMed ID: 11793337 [TBL] [Abstract][Full Text] [Related]
13. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment. Smith TS; Trimmer PA; Khan SM; Tinklepaugh DL; Bennett JP Brain Res; 1997 Aug; 765(2):189-97. PubMed ID: 9313891 [TBL] [Abstract][Full Text] [Related]
14. Primary cilia in Parkinson's disease: summative roles in signaling pathways, genes, defective mitochondrial function, and substantia nigra dopaminergic neurons. Tian Z; Zhang Y; Xu J; Yang Q; Hu D; Feng J; Gai C Front Aging Neurosci; 2024; 16():1451655. PubMed ID: 39364348 [TBL] [Abstract][Full Text] [Related]
15. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease. Li H; He Z; Su T; Ma Y; Lu S; Dai C; Sun M Neurol Res; 2003 Apr; 25(3):263-7. PubMed ID: 12739234 [TBL] [Abstract][Full Text] [Related]
16. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity. Oeckl P; Ferger B Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149 [TBL] [Abstract][Full Text] [Related]
17. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Al-Sweidi S; Morissette M; Bourque M; Di Paolo T Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296 [TBL] [Abstract][Full Text] [Related]